SRZN

Surrozen, Inc. (SRZN) - Q2 2024 10-Q Summary

Business Context and Reporting Period

Surrozen, Inc. is a clinical-stage biotechnology company developing drug candidates to modulate the Wnt pathway for tissue repair. This report covers the quarterly period ended June 30, 2024. The company is classified as an emerging growth company and a smaller reporting company. Its lead product candidates include SZN-043 (severe alcohol-associated hepatitis) and SZN-413 (retinal vascular-associated diseases, in collaboration with Boehringer Ingelheim).

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Increase: Net loss for the six months ended June 30, 2024, increased by $10.4 million (44%) compared to the same period in 2023. This was primarily driven by a $20.4 million non-cash loss on the issuance of common stock, pre-funded warrants, and warrants in a private placement closed in April 2024.
• Operating Expense Reduction: Total operating expenses decreased by $6.7 million (27%) year-over-year for the six-month period. This reduction is attributed to workforce reductions implemented in 2023 and the discontinuation of the SZN-1326 clinical program in January 2024.
• Warrant Liability Volatility: Warrant liabilities increased significantly from $0.1 million at December 31, 2023, to $33.0 million at June 30, 2024, due to the fair value of warrants issued in the April 2024 private placement.
• Cash Flow: Net cash used in operating activities improved to $14.4 million for the six months ended June 30, 2024, compared to $22.9 million in the prior year period, reflecting lower operating costs.

Guidance, Outlook, and Risks

• Liquidity: As of June 30, 2024, the company held $37.8 million in cash and cash equivalents. Management believes this is sufficient to fund operations for at least the next 12 months. However, the company anticipates needing to raise additional capital to execute its long-range business plan.
• Private Placement: In April 2024, the company raised approximately $16.0 million in net proceeds through a private placement. This included the issuance of common stock and warrants exercisable upon the achievement of specific clinical milestones (e.g., patient enrollment in SZN-043 trials).
• Clinical Progress: The company has initiated enrollment in the Phase 1b clinical trial for SZN-043. Proof-of-concept data is anticipated in the first half of 2025. The Phase 1a study showed acceptable safety, though asymptomatic transaminase elevations were observed.
• Risks: Key risks include the high cost of clinical development, the uncertainty of clinical trial outcomes (specifically regarding safety signals in SZN-043), the need for future capital raises which may cause dilution, and the potential for warrant liabilities to fluctuate based on stock price and milestone probabilities.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $37.8 million cash balance against the projected burn rate for the SZN-043 Phase 1b trial and general operations.
• Warrant Liability Impact: Assess the potential for future non-cash gains or losses on the $33.0 million warrant liability, which is sensitive to stock price volatility and milestone achievement probabilities.
• Dilution Risk: Review the terms of the April 2024 private placement warrants (Series A-D), noting that a significant portion is only exercisable upon meeting specific clinical milestones, which could lead to substantial dilution if achieved.
• Safety Signals: Monitor upcoming data regarding the asymptomatic transaminase elevations observed in the SZN-043 Phase 1a trial and their impact on the Phase 1b trial design or continuation.
• Collaboration Milestones: Track progress on the SZN-413 collaboration with Boehringer Ingelheim, specifically the potential $10.0 million milestone payment for nominating a lead candidate in 2024.